We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Bimatoprost 0.01 % for previously treated patients with open-angle glaucoma or ocular hypertension in the Korean clinical setting.
- Authors
Kook, Michael; Simonyi, Susan; Sohn, Yong; Kim, Chan; Park, Ki
- Abstract
Purpose: To evaluate the occurrence of hyperemia with, and efficacy of, bimatoprost 0.01 % for patients in Korea previously treated for open-angle glaucoma (OAG; including normal tension glaucoma) or ocular hypertension (OHT). Methods: In this multicenter, observational study (Asia Pacific Patterns from Early Access of Lumigan 0.01 % in Korea; APPEAL Korea), patients with unachieved target intraocular pressure (IOP) despite previous treatment received bimatoprost 0.01 % daily for 12 weeks. The primary endpoint was incidence of hyperemia and its severity, graded using the standard 5-point photographic scale and grouped as 'none to mild' and 'moderate to severe'. Hyperemia shifts were reported. IOP and adverse events (AEs) were recorded. Results: Of 800 patients (intent-to-treat/safety population), 248 were switched from previous treatment to bimatoprost 0.01 % monotherapy. Hyperemia shifts from baseline at weeks 6 and 12 were unchanged (84.8, 89.8 %), improved (4.4, 4.8 %), or worsened (10.8, 5.4 %), respectively. The shift was significant at week 6 ( P < 0.0001). Hyperemia did not worsen significantly in patients previously receiving a prostaglandin analog or prostamide (PGA/PSD). Baseline mean IOP ± SD was 17.0 ± 5.7 mmHg, decreasing to 14.6 ± 3.8 mmHg ( P < 0.0001) after 6 weeks, and to 14.7 ± 3.6 mmHg ( P < 0.0001) after 12 weeks. Patients switched from PGA or PSD (excluding bimatoprost 0.03 %) to bimatoprost 0.01 % experienced significant IOP reductions from baseline. Treatment-related ocular AEs were reported by 37 patients, the most common being hyperemia (7.3 %). Conclusions: This subanalysis of the APPEAL Korea study supports use of bimatoprost 0.01 % for previously treated patients with OAG (including normal tension glaucoma) or OHT who did not reach target IOP or were intolerant of previous treatment.
- Subjects
HYPEREMIA; BIMATOPROST; DRUG efficacy; OPEN-angle glaucoma; OCULAR hypertension; INTRAOCULAR pressure; DRUG side effects
- Publication
Japanese Journal of Ophthalmology, 2015, Vol 59, Issue 5, p325
- ISSN
0021-5155
- Publication type
Article
- DOI
10.1007/s10384-015-0392-2